IP Library › Granted Patent US 12678471
Granted Patent B2
US 12678471 · App. 18/154,879 · Granted Jul 14, 2026

Method for inhibiting infection of SARS-CoV-2 in a subject

Inventors: Tsong-Long Hwang (Taoyuan City, TW); Yu-Li Chen (Taoyuan City, TW); Michal Korinek (Kaohsiung City, TW); Marcela Safratova (Hradec kralove, CZ); Anna Hostalkova (Hradec Kralove, CZ)
Assignee: Chang Gung University of Science and Technology
A61K36/29A61K31/4741A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678471
App. No.
18/154,879
Granted
Jul 14, 2026
Kind
B2
Abstract

A method for inhibiting infection of SARS-CoV-2 in a subject is provided, including administering to the subject a compound, wherein the compound comprises Aromoline, Obamegine, Berbamine or Bersavine.

Claims (7)

1 . A method for inhibiting infection of SARS-CoV-2 in a subject, comprising administering a compound to the subject, wherein the compound is Obamegine or Bersavine, and the SARS-CoV-2 is omicron variant.

2 . The method of claim 1 , wherein the compound is extracted from a plant of the barberry family (Beriberidaceae).

3 . The method of claim 2 , wherein the plant of the barberry family (Beriberidaceae) is Berberis vulgaris.

4 . The method of claim 1 , wherein the compound is an alcohol extract extracted from the plant of the barberry family (Beriberidaceae).

5 . The method of claim 4 , wherein the plant of the barberry family (Beriberidaceae) is Berberis vulgaris.

6 . The method of claim 1 , wherein the compound inhibits infection of SARS-CoV-2 in the subject by blocking the binding of spike proteins on the SARS-CoV-2 and angiotensin-converting enzyme 2 on the subject's cells.

7 . The method of claim 1 , wherein the subject is a human or a mammal.